Houston、TXにおける前立腺がんの臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、前立腺がんに関する76件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
被験者募集中第1/2相
- Research Site, Houston
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
被験者募集中第2相
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
被験者募集中第3相
- Houston Metro Urology (HMU), Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- University of Texas MD Anderson Cancer Center, Houston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- UT MD Anderson Cancer Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- The University of Texas MD Anderson Cancer Center, Houston
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
被験者募集中早期第1相
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
被験者募集中第3相
- Texas Oncology - Gulf Coast ( Site 8002), Houston
Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer
被験者募集中
- M D Anderson Cancer Center, Houston
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
被験者募集中第1/2相
- Research Site, Houston
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
被験者募集中第1相
- NEXT Houston, Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
被験者募集中第3相
- Renovatio Clinical, Houston
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
被験者募集中第3相
- Research Site, Houston
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
被験者募集中第2相
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
被験者募集中第3相
- University of Texas-MD Anderson Cancer Center ( Site 0055), Houston
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
被験者募集中第1相
- University of Texas MD Anderson Cancer Center, Houston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
被験者募集中第3相
- UT MD Anderson Cancer Center, Houston
- MD Anderson West Houston, Houston
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
被験者募集中第1相
- Investigational Site Number: 401, Houston
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
被験者募集中第1相
- UT MD Anderson, Houston
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
被験者募集中第1/2相
- Research Site, Houston
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
被験者募集中第3相
- Research Site, Houston
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
被験者募集中第1/2相
- M D Anderson Cancer Center, Houston
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
被験者募集中第1相
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
被験者募集中第1/2相
- Oncology Consultants, P.A, Houston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
被験者募集中第2相
- Oncology Consultants, Houston
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
被験者募集中第2相
- U.T. MD Anderson Cancer Center, Houston
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
被験者募集中第1相
- The University of Texas M. D. Anderson Cancer Center, Houston
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
被験者募集中
- The University of Texas MD Anderson Cancer Center, Houston
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
被験者募集中第1相
- Houston Methodist Hospital, Houston
Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance
被験者募集中観察研究
- M D Anderson Cancer Center, Houston
A Study of DM002 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- The University of Texas, MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
被験者募集中第3相
- MD Anderson Cancer Center, Houston
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
被験者募集中第1/2相
- M D Anderson Cancer Center, Houston
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
被験者募集中第2相
- UT MD Anderson Cancer Center, Houston
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
被験者募集中第3相
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- Houston Methodist Hospital, Houston
- 他4件
Stem Cells for Erectile Dysfunction Post RALP
被験者募集中第1/2相
- Houston Methodist, Houston
Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson Hospital
被験者募集中
- The University of Texas M. D. Anderson Cancer Center, Houston
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
被験者募集中第2相
- M D Anderson Cancer Center, Houston
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
被験者募集中第2相
- Michael E. DeBakey VA Medical Center, Houston
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
被験者募集中第2相
- M D Anderson Cancer Center, Houston
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
被験者募集中第1/2相
- Next Oncology - Houston, Houston
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
被験者募集中第4相
- UT Health Science Center, Houston
An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
被験者募集中第2相
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing
被験者募集中観察研究
- M D Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
被験者募集中
- M D Anderson Cancer Center, Houston
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
被験者募集中第2/3相
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
被験者募集中第1/2相
- Houston Methodist, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
被験者募集中観察研究
- Md Anderson Cancer Center, Houston
Study of AZD0754 in Participants With Metastatic Prostate Cancer
被験者募集中第1/2相
- Research Site, Houston
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
被験者募集中第1相
- Houston Metro Urology, Houston
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
被験者募集中第3相
- Lyndon Baines Johnson General Hospital, Houston
- M D Anderson Cancer Center, Houston
- MD Anderson West Houston, Houston
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Oncology Consultants, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
被験者募集中第2相
- Ben Taub General Hospital, Houston
- Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Houston
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
被験者募集中第3相
- Lyndon Baines Johnson General Hospital, Houston
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- 他3件
Comprehensive Assessment of Cancer Theranostic Response
被験者募集中
- M.D. Anderson Cancer Center, Houston
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #1, Houston
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
被験者募集中第2相
- Excel Diagnostics & Nuclear Oncology Center, Houston
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing
被験者募集中観察研究
- M.D. Anderson Cancer Center, Houston
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Comprehensive Outcomes for After Cancer Health
被験者募集中健康なボランティア歓迎
- The University of Texas MD Anderson Cancer Center, Houston
- UT Health Houston, Houston
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
被験者募集中第2相
- M D Anderson Cancer Center, Houston
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
被験者募集中第2相
- Houston Methodist Hospital, Houston
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
被験者募集中第1/2相
- Houston Methodist, Houston
他の都市における前立腺がんの試験
- New York City, NY103件の研究
- Los Angeles, CA61件の研究
- Boston, MA59件の研究
- St. Louis, MO46件の研究
- Chicago, IL45件の研究
- San Francisco, CA45件の研究
- Philadelphia, PA44件の研究
- Baltimore, MD43件の研究
- Nashville, TN43件の研究
- Seattle, WA42件の研究
- Washington, DC38件の研究
- Dallas, TX36件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
- 頭頸部扁平上皮癌47件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。